Thanks
As of Sept 30, 2024, cash was $7.1M and obligations including leases were $9.2M. 12-month cash flow was $0.9M. 2023 ROE was 2.47%. P/E is 33X. Due to its very small size we do not pay close attention to it. It did have a solid Q3 with 78% growth. The acquisition of the compounding pharmacy is quite big for the company at $22.5M. It is accretive to all metrics but will add debt and dilution through the share part of the deal. The deal has closed, and thus debt has increased by nearly $19M from the Sept. 30 numbers. It is an aggressive move, and we will need to see that it performs as expected.